Osteogenic Growth Peptide (10-14) (OGP(10-14)) is a C-terminal truncated pentapeptide of osteogenic growth peptide (OGP) that retains intact OGP-like activity. Osteogenic Growth Peptide (10-14) binds to OGP receptors and activates the intracellular Gi protein kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and bone- and hematopoietic factor. Osteogenic Growth Peptide (10-14) is a Src inhibitor.

Physicochemical Properties

Molecular Formula	C24H29N5O7
Molecular Weight	499.52
Exact Mass	499.207
CAS #	105250-85-9
PubChem CID	147077
Appearance	White to off-white solid powder
Density	1.352g/cm3
Boiling Point	1028ºC at 760mmHg
Flash Point	575.5ºC
Vapour Pressure	0mmHg at 25°C
Index of Refraction	1.609
LogP	0.686
Hydrogen Bond Donor Count	7
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	13
Heavy Atom Count	36
Complexity	764
Defined Atom Stereocenter Count	2
SMILES	C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
InChi Key	BGFPKYKDLYYTJH-OALUTQOASA-N
InChi Code	InChI=1S/C24H29N5O7/c25-18(10-16-6-8-17(30)9-7-16)23(35)27-13-21(32)29-19(11-15-4-2-1-3-5-15)24(36)28-12-20(31)26-14-22(33)34/h1-9,18-19,30H,10-14,25H2,(H,26,31)(H,27,35)(H,28,36)(H,29,32)(H,33,34)/t18-,19-/m0/s1
Chemical Name	2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetic acid
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	Osteogenic Growth Peptide (10-14) (OGP(10-14)) stimulates proliferation and differentiation in fibroblast and osteoblast cell lines[3]. Osteogenic Growth Peptide (10-14) stimulates TPO-primed M07-e cells differentiation through RhoA/ TGFβ1/SFKs signaling pathway. In particular Historphin functions as a Src inhibitor, displaying the same effects of PP2[4].
ln Vivo	In mice and rats, administration of Osteogenic Growth Peptide (10-14) (OGP(10-14)) promotes fracture healing and enhances trabecular bone density and bone formation[1].
References	[1]. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002;45(8):1624-1632. [2]. Regulation of endochondral ossification by osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)]. Protein Pept Lett. 2009;16(9):1074-1080. [3]. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk Res. 2002;26(1). [4]. The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Med Sci Monit. 2011;17(1):SC1-SC5.

Solubility Data

Solubility (In Vitro)

DMSO: 8.93 mg/mL (17.88 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 0.89 mg/mL (1.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.9 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.89 mg/mL (1.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.9 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 0.89 mg/mL (1.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.9 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.0019 mL	10.0096 mL	20.0192 mL
	5 mM	0.4004 mL	2.0019 mL	4.0038 mL
	10 mM	0.2002 mL	1.0010 mL	2.0019 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.